© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Analysis of nearly 34,000 people finds no serious adverse events associated with direct-acting antiviral therapy.
Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.
Stella Armstrong’s journey to a healthier life wasn’t easy.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
Between August 2018 and January 2019, the FDA doubled the number of liver cancer treatments.
Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.
Responding to the increasing incidence of liver cancer in the United States
A new systematic review and meta-analysis indicates that hepatitis C is most notably also associated with B-cell non–Hodgkin lymphoma.
Researchers compared outcomes among those with and without hep C before and after Sovaldi was approved in late 2013.
With the approval of Cyramza, there are now five targeted therapies for hepatocellular carcinoma.
The drug is still associated with a lower liver cancer rate than Baraclude.
A quick overview of Hep Magazine’s reporting on the 53rd International Liver Congress in Vienna
Curing the virus was associated with a lower risk of liver cancer recurrence.
Do you know your liver cancer risk?
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
